期刊文献+

Fas FasL在Bowen病和鳞状细胞癌中的表达及意义 被引量:3

Expression of Fas and Fas Ligand in Bowen's Disease and Squamous Cell Carcinoma.
下载PDF
导出
摘要 目的 探讨由Fas 和FasL 介导的凋亡在Bowen 病和鳞状细胞癌(SCC) 局部免疫反应中的作用。方法 采用免疫组化对Bowen 病、SCC 不同恶性度分级的皮损蜡块组织中Fas 、FasL 表达情况进行检测。结果 Fas 、FasL 在Bo wen 病和SCC 上均表达,但随肿瘤恶性程度升高Fas 表达逐渐减弱,而FasL 表达逐渐增强。结论 由Fas 系统介导的凋亡所引发的异常免疫杀伤作用可能参于某些表皮肿瘤局部免疫逃避机制,从而与肿瘤良恶性分级、预后有一定关系。 Objective To study the function of apoptosis mediated by Fas and Fas ligand in Bowen's disease and sqamous cell carcoma(SCC).Method The immunohistochemistry was empolyed to show the expression of Fas and Fas ligand in Bowen's Disease and SCC.Results The positive rates of Fas and Fas ligand in Bowen's Disease and SCC were both 100%,the intense of expressions of Fas was downregulated and that of Fas ligand was upregulated along with the increasing malignant degree of tumors.Conclusions Expression of Fas and Fas ligand are related to degree of epidermal tumors,and apoptosis mediated by Fas and Fas ligand may be one cause responsible to epidermal tumor's local immune evasion.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2000年第1期10-12,共3页 The Chinese Journal of Dermatovenereology
关键词 FAS FASL BOWEN病 鳞状细胞癌 皮肤肿瘤 Fas Fas Ligand Apoptosis Bowen's Disease Squamous Cell cacinoma
  • 相关文献

参考文献10

  • 1Suda T, Takahashi T, Golstein P, etal. Molecular coloning and expression of the Fas Ligand: a novel member of the turmornecrosis factor family. Cell, 1993,75:1169~1178.
  • 2Griffith TS, Brunner T, Fleteher SM, et al. Fas Ligand induced apoptosis as amechanism of immune privilege. Science, 1995,270:1189.
  • 3Lee SH,Jang JJ, Lee JY, et al. Fas ligand is expressed in normal skin and in somecutaneous maligancies. Br J Dermatol, 1998,139:186.
  • 4Berthou C, Michel L, Soulie A, et al. Acquisition of granzyme B and Fas ligandprotein by human keratinocytes contributes to epidermal cell defense. J Immunol,1997,159:5293~5300.
  • 5Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95)ligand: implications for tumor immune escape. Science, 1996,274:1363 ~ 1366.
  • 6Maeda. A, Aragane Y, lezuka T. Expression of CD95 Ligand in melanocytic lesions asa diagnostic marker. Br J Dermatol, 1998,139:198.
  • 7Sato T, Irie S, Kitada S, et al. FAP-1: a protein tyrosine phosphatase thatassociates with Fas. Science, 1995,268: 411.
  • 8Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellularFILP. Nature, 1997,388:190.
  • 9Cheng J ,Zhou T, Liu C, et al. Protection from Fas-madiated apoptosis by a solubleform of the Fas molecule. Science, 1994,263:1759.
  • 10Rienx-laucat T, Le Deist T, Hirroz C, et al. Mutations in Fas associated withhuman lymphoproliferative syndrome and autoimmunity. Science, 1995,268:1347.

同被引文献29

  • 1马三成,马斌林,Paul Speight.口腔粘膜癌前病变HPV感染与p53蛋白过度表达[J].新疆医科大学学报,2004,27(6):619-621. 被引量:2
  • 2姜福金,周齐军,蒋家骏,马松,刘贤平,郑骏年,孙晓青.肾癌Fas和FasL蛋白表达异常对其免疫逃避机制的影响[J].中国医师杂志,2005,7(6):724-727. 被引量:3
  • 3李印,郑世营,葛锦峰,邵峰,纪勇,蒋东.FasL基因表达与食管癌免疫逃逸关系的研究[J].胃肠病学和肝病学杂志,2005,14(6):594-596. 被引量:2
  • 4穆雅琴,赵富玺,郭俊成,刘润花.宫颈癌凋亡抑制因子表达与HPV_(16/18)感染相关性[J].中国公共卫生,2006,22(12):1416-1418. 被引量:9
  • 5Lee TB,Min YD,Lim SC,et al.Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells[J].J Gastroenterol Hepatol,2002,17:32-38.
  • 6Owen-Schaub L,Chan H,Cusack JC,et al.Fas and Fas ligand interactions in malignant disease[J].Int J Oncol,2000,17:5-12.
  • 7Lee SH,Jang JJ,Lee JY,et al. Fas ligand is expressed in normal skin and in some cutaneous malignancies [ J ]. Br Dermatol, 1998, 139 (2) :186-191.
  • 8郭亚军,时玉舫.细胞学与肿瘤免疫学研究进展[M].第1版.北京:军事医学科学出版社,2000.10-23.
  • 9Dayan CM, Elsegood KA, Podack ER, et al. Fas ligand expression on epithelial cells [ J ]. Immunol Today, 1997,18 (5) :203-208.
  • 10Shiraki K, Tsuji N, Shloda T, et al. Expression of Fas llgand in liver metastases of human colon adenocarcinomas [ J ]. Proc Natl Acad Sci U S A, 1997,94(12) :6420-6425.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部